Therefore, we plan to investigate whether administering a mixture of leptin inhibitor together with a CCL2 inhibitor to tumor bearers will result in a better approach to reduce tumor progression and adipose tissue inflammation in this tumor model with DIO mice. This evidence concerns the gene CCL2 and neoplasm.